V. Battistel

Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: findings from the Anemia Cancer Treatment study.

C. Bokemeyer, M. Aapro, H. Ludwig, 2013, Journal of geriatric oncology.

Clinical and biological effects of erythropoietin treatment of myelodysplastic syndrome.

T. Barbui, C. Caslini, A. Rambaldi, 1993, Leukemia & lymphoma.

Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.

G. Poggi, P. Pedrazzoli, V. Rosti, 1992, Haematologica.

Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.

Gerard N. Jager, R. Greil, M. Cazzola, 1995, Blood.

Erythropoietin, aluminium, and anaemia in patients on haemodialysis

G. Barosi, A. Salvadeo, V. Piazza, 1990, The Lancet.

THERAPY WITH HUMAN RECOMBINANT ERYTHROPOIETIN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

T. Barbui, C. Caslini, A. Rambaldi, 1992, British journal of haematology.

[Comparative study of defibrotide and calcium heparin in the prevention of postoperative deep venous thrombosis. A randomized multicenter study].

A. De Rosa, V. Battistel, 1988, Minerva medica.